The Zhejiang University Future Capital-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.

Harbour BioMed, a US-based immuno-oncology and inflammatory disease therapy developer backed by university venture fund Zhejiang University Future Capital, raised $102.8m in series C funding yesterday.
Asset manager Hudson Bay Capital led the round, while OrbiMed, Country Garden VC, GTJA Investment Group, Octagon Capital, Sage Partners and Greater Bay Area Investment Fund also took part.
Founded in 2016 to acquire transgenic antibody developer Harbour Antibodies, Harbour BioMed is working on antibodies to treat cancer, inflammatory diseases and Covid-19.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in